AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

GRI Bio, Inc.

$1.94 -$5.90 (-75.26%)
NASDAQ · 14 Sep 2026 18:29 UTC
Previous Close
$1.9
Day Range
$1.86$1.97
Year Range
$1.36$64.12
Market Cap
174.27K
AVG Volume
251.26K
Trailing/Forward PE
-0.04/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
NASDAQUS
Revenue (USD)
025K50K75K100K2019202020212022202320242025
GRI Revenue (USD) by year
PeriodRevenue (USD)
20250
20240
20230
20220
20210
2020100K
20190
Net Income (USD)
-15M-10M-5M02019202020212022202320242025
GRI Net Income (USD) by year
PeriodNet Income (USD)
2025-11.96M
2024-8.21M
2023-13.04M
2022-5.55M
2021-9.3M
2020-4.82M
2019-3.46M
Operating Income (USD)
-15M-10M-5M02019202020212022202320242025
GRI Operating Income (USD) by year
PeriodOperating Income (USD)
2025-11.98M
2024-8.24M
2023-11.39M
2022-4.68M
2021-9.26M
2020-4.79M
2019-3.16M
EBITDA (USD)
-15M-10M-5M02019202020212022202320242025
GRI EBITDA (USD) by year
PeriodEBITDA (USD)
2025-11.97M
2024-8.2M
2023-10.92M
2022-4.95M
2021-9.27M
2020-4.77M
2019-3.27M
Cash Flows (USD)
-15M-10M-5M02019202020212022202320242025
GRI Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-10.59M
2024-8.61M
2023-9.15M
2022-1.09M
2021-8.31M
2020-1.87M
2019-694.74K
EPS (USD)
-1500000-1000000-50000002019202020212022202320242025
GRI EPS (USD) by year
PeriodEPS (USD)
2025-240.26
2024-5100.76
2023-140450.24
2022-714242.2
2021-1184549.24
2020-919973.04
2019-660980.6
Expenses (USD)
05M10M15MR&DSG&ACapex2019202020212022202320242025
GRI Expenses (USD) by year
PeriodExpenses (USD)
202512.38M
20248.23M
202311.38M
20224.65M
20219.18M
20204.87M
20193.16M
Cash & Debt (USD)
02.5M5M7.5M10MCashLong Term DebtShort Term Debt2019202020212022202320242025
GRI Cash & Debt (USD) by year
PeriodCash & Debt (USD)
20258.23M
20245.03M
20231.81M
20229K
20217.51M
2020109K
20193.82M
Debt ratios
-0.100.10.20.32022202320242025
GRI Debt ratios by year
PeriodDebt ratios
20250.23
20240.15
20230.06
2022-0.03
Margins
-20%-15%-10%-5%0%2020
GRI Margins by year
PeriodMargins
2020-19%
Return on Capital
-6000%-4000%-2000%0%2000%2019202020212022202320242025
GRI Return on Capital by year
PeriodReturn on Capital
2025-199%
2024-203.57%
2023-5033.59%
2022341.54%
2021-159.9%
2020331.64%
2019-107.8%
Shares Outstanding
0200K400K600K2019202020212022202320242025
GRI Shares Outstanding by year
PeriodShares Outstanding
2025497.7K
20246.55K
20231.77K
20221.76K
2021891
2020891
2019891
Dividends (USD)
00.511.52008
GRI Dividends (USD) by year
PeriodDividends (USD)
20080.49
Book Value Per Share (USD)
-250002500500075002019202020212022202320242025
GRI Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
202512.07
2024615.95
2023146
2022-921.2
20216529.74
2020-1631.87
20193606.96
Total Assets (USD)
02.5M5M7.5M10M2019202020212022202320242025
GRI Total Assets (USD) by year
PeriodTotal Assets (USD)
20258.67M
20245.74M
20232.96M
2022383K
20218.34M
2020955K
20194.28M
Free Cash Flow Yield
-6000%-4000%-2000%0%med -349.08%Jan 23May 23Oct 24Jan 25Feb 26May 26Sep 26
GRI Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-303.78%
Sep 26-200.41%
Aug 26-300.62%
Aug 26-349.81%
Aug 26-345.62%
Aug 26-665.36%
Jul 26-1541.16%
Jul 26-1466.76%
Jul 26-1417.87%
Jul 26-1222.3%
Jul 26-1137.33%
Jun 26-1168.57%
Jun 26-1131.28%
Jun 26-945.24%
Jun 26-1063.4%
May 26-1032.43%
May 26-1032.43%
May 26-1047.68%
May 26-945.24%
May 26-975.6%
Apr 26-916.72%
Apr 26-834.04%
Apr 26-868.08%
Apr 26-893.61%
Mar 26-932.81%
Mar 26-901.19%
Mar 26-4041.08%
Mar 26-3993.91%
Feb 26-4025.24%
Feb 26-4122.23%
Feb 26-4443.44%
Feb 26-4294.71%
Jan 26-3148.57%
Jan 26-1819.92%
Jan 26-1647.57%
Jan 26-1629.26%
Jan 26-1309.23%
Dec 25-1327.86%
Dec 25-1078.19%
Mar 25-1092.97%
Mar 25-998%
Feb 25-826.63%
Feb 25-927.32%
Feb 25-700.2%
Feb 25-804.29%
Jan 25-609.58%
Jan 25-626.5%
Jan 25-534.44%
Jan 25-505.16%
Jan 25-424.57%
Dec 24-495.6%
Dec 24-520.42%
Dec 24-180.16%
Dec 24-182.44%
Nov 24-210.86%
Nov 24-209.24%
Nov 24-186.61%
Nov 24-164.66%
Nov 24-131.03%
Oct 24-201%
Oct 24-248.5%
Oct 24-357.17%
Oct 24-402.33%
Sep 24-323.25%
Sep 24-327.13%
Sep 24-340.6%
Sep 24-333.95%
Aug 24-337.05%
Aug 24-336.27%
Aug 24-348.35%
Aug 24-329.04%
Aug 24-317.55%
May 23-0.25%
May 23-0.23%
May 23-0.23%
May 23-0.2%
Apr 23-0.2%
Apr 23-0.12%
Apr 23-0.13%
Apr 23-0.12%
Mar 23-0.13%
Mar 23-0.12%
Mar 23-0.11%
Mar 23-0.11%
Mar 23-0.12%
Feb 23-0.15%
Feb 23-0.11%
Feb 23-0.19%
Feb 23-0.31%
Jan 23-0.32%
Jan 23-0.3%
Jan 23-0.33%
Jan 23-0.32%
Dec 22-0.31%
Dec 22-0.31%
Dec 22-0.3%
Dec 22-0.39%
Dec 22-0.37%
Nov 22-0.81%
Nov 22-0.74%
Price to Sales
400006000080000100000med 53318.38Feb 21Mar 21Mar 21Apr 21May 21May 21
GRI Price to Sales by year
PeriodPrice to Sales
May 2146313.47
May 2144345.14
May 2142376.82
May 2147239.74
Apr 2149555.41
Apr 2151986.87
Apr 2152681.57
Apr 2153955.19
Apr 2156502.43
Mar 2151060.6
Mar 2158123.4
Mar 2164375.72
Mar 2157903.41
Feb 2170743.82
Feb 2181511.7
Feb 2190658.61
Price to Book
051015med 0.61Jul 24Nov 24Feb 25Oct 25Feb 26May 26Sep 26
GRI Price to Book by year
PeriodPrice to Book
Sep 260.33
Sep 260.51
Aug 260.34
Aug 260.29
Aug 260.29
Aug 260.17
Jul 260.11
Jul 260.12
Jul 260.12
Jul 260.14
Jul 260.15
Jun 260.15
Jun 260.16
Jun 260.19
Jun 260.17
May 260.17
May 260.17
May 260.17
May 260.19
May 260.18
Apr 260.19
Apr 260.21
Apr 260.2
Apr 260.2
Mar 260.19
Mar 260.2
Mar 260.12
Mar 260.12
Feb 260.12
Feb 260.12
Feb 260.11
Feb 260.11
Jan 260.15
Jan 260.26
Jan 260.29
Jan 260.3
Jan 260.37
Dec 250.36
Dec 250.45
Dec 250.35
Dec 251.37
Nov 251.33
Nov 251.36
Nov 251.12
Nov 251.12
Oct 251.13
Oct 251.36
Oct 251.29
Oct 251.23
Oct 251.27
Sep 251.29
Sep 251.2
Sep 251.2
Sep 250.72
Aug 250.61
Aug 250.61
Aug 250.61
Mar 250.3
Mar 250.33
Feb 250.4
Feb 250.36
Feb 250.47
Feb 250.41
Jan 250.55
Jan 250.53
Jan 250.62
Jan 250.66
Jan 250.78
Dec 240.67
Dec 240.64
Dec 241.32
Dec 241.3
Nov 241.13
Nov 241.14
Nov 241.27
Nov 241.44
Nov 241.81
Oct 241.18
Oct 240.96
Oct 240.67
Oct 240.59
Sep 240.74
Sep 240.73
Sep 240.97
Sep 240.99
Aug 240.98
Aug 240.98
Aug 240.95
Aug 241
Aug 241.04
Jul 244.11
Jul 245.44
Jul 245.67
Jul 245.12
Jun 246.26
Jun 248.67
Jun 249.66
Jun 2411.8
May 2412.8
May 2413.48
GRI Bio, Inc.
GRI
Stockpicker

Video analysis: GRI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: GRI

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

zacks.com · 14 Sep 2026

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

GRI Bio, Inc. (GRI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

benzinga.com · 14 Sep 2026

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

globenewswire.com · 8 Sep 2026

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection

GRI Bio Featured in "Why Now" On-Demand Video Webcast

globenewswire.com · 27 Aug 2026

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available  here

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

globenewswire.com · 24 Aug 2026

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9, 2026 in Barcelona, Spain.

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

nypost.com · 20 Aug 2026

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

gurufocus.com · 5 Aug 2026

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

Ingevity Corporation (NYSE: NGVT) today announced it has published its [url="]2025 Sustainability Report[/url] featuring the company's advanced materials and tec

Ingram Micro Releases 2025 Sustainable Impact Report

gurufocus.com · 3 Aug 2026

Ingram Micro Releases 2025 Sustainable Impact Report

Ingram Micro today released its 2025 Sustainable Impact Report, detailing the company's progress made through 2025 to reduce carbon emissions, advance zero-wast

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.